Last reviewed · How we verify
NCT05349071
PreOperative Methylprednisolone on Thoracic Endovascular Repair for Reducing Post-implantation Syndrome (POMTEVAR)
NA trial testing methylprednisolone in Methylprednisolone in 158 participants. Status unknown.
1 May 2024
Quick facts
| Lead sponsor | Guangdong Provincial People's Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 158 |
| Start date | 1 May 2022 |
| Primary completion | 1 May 2024 |
| Estimated completion | 1 October 2024 |
Drugs / interventions tested
- methylprednisolone (methylprednisolone) — full drug profile →
- physiological saline — full drug profile →
Conditions studied
- Methylprednisolone — all drugs for Methylprednisolone →
- Thoracic Endovascular Repair — all drugs for Thoracic Endovascular Repair →
- Post-implantation Syndrome — all drugs for Post-implantation Syndrome →
- Type B Aortic Dissection — all drugs for Type B Aortic Dissection →
Sponsor
Guangdong Provincial People's Hospital
Who can join
18 and older, any sex, with Methylprednisolone or Thoracic Endovascular Repair. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
POMTEVAR trial is a multicenter, open-label and prospective random controlled study. Approximately 158 patients will be randomly allocated to thoracic endovascular repair (TEVAR) alone group or TEVAR plus methylprednisolone group and managed with respective treatment strategies. All study patients will be followed up in the outpatient clinic and undergo CT scans after 3 months from randomization. The primary objective is to test the hypothesis that PIS is lower in TEVAR plus methylprednisolone group than that in TEVAR alone group. The secondary objective is to test the hypothesis that changes of postoperative inflammatory indicators, incidence of postoperative acute renal failure and postoperative delirium, postoperative pain score are lower in TEVAR plus methylprednisolone group than that in TEVAR alone. In addition, 3-month all-cause death, 3-month major adverse cardiovascular events, 3-month aorta-related adverse events and 3-month aortic remodeling are compared between groups.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05349071
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of methylprednisolone
Trials testing the same drug.
- NCT07525466 — Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatm · Phase 1, PHASE2 · recruiting
- NCT07412470 — A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantati · Phase 2, PHASE3 · recruiting
- NCT06623370 — The Effect of Methylprednisolone on the Reversal Time of Rocuronium by Sugammadex in the Pediatric Patient Group · Phase 4 · completed
- NCT04826237 — Oral Statins and Protection From Hearing Loss · Phase 4 · recruiting
- NCT05137496 — Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome · Phase 3 · unknown
Other Guangdong Provincial People's Hospital trials
Trials by the same sponsor.
- NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
- NCT07514611 — Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial · NA · recruiting
- NCT07352930 — A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Can · NA · not yet recruiting
- NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
- NCT07483398 — RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05349071 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial People's Hospital
- Last refreshed: 27 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05349071.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing